JBIO vs. CRSP

Last updated Jun 5, 2026

JBIO (Jade Biosciences, Inc) and CRSP (CRISPR Therapeutics AG) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, JBIO returned -32.72%/yr vs -3.33%/yr for CRSP. At a 0.29 correlation, their price movements are largely independent.

Performance

JBIO vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Jade Biosciences, Inc (JBIO) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, JBIO achieves a 14.97% return, which is significantly higher than CRSP's 8.60% return.

JBIO

• 1D: 0.85%
• 1M: -29.77%
• YTD: 14.97%
• 6M: 43.06%
• 1Y: 146.05%
• 3Y*: -32.72%
• 5Y*: —
• 10Y*: —

CRSP

• 1D: 9.35%
• 1M: 8.72%
• YTD: 8.60%
• 6M: -2.11%
• 1Y: 49.67%
• 3Y*: -3.33%
• 5Y*: -12.85%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

JBIO vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
JBIO Jade Biosciences, Inc	14.97%	59.23%	-88.29%	-22.76%	148.52%	-48.36%
CRSP CRISPR Therapeutics AG	8.60%	33.23%	-37.12%	54.00%	-46.36%	-53.19%

Correlation

The correlation between JBIO and CRSP is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.35
Correlation (3Y) Calculated over the trailing 3-year period	0.33
Correlation (All Time) Calculated using the full available price history since Jul 1, 2021	0.29

Fundamentals

Market Cap JBIO : $1.02B CRSP : $5.47B
EPS JBIO : -$2.96 CRSP : -$6.24
PB Ratio JBIO : 3.46 CRSP : 3.01
Total Revenue (TTM) JBIO : $0.00 CRSP : $4.10M
Gross Profit (TTM) JBIO : -$9.00K CRSP : -$171.17M
EBITDA (TTM) JBIO : -$133.57M CRSP : -$509.21M

Return for Risk

JBIO vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JBIO

JBIO Risk / Return Rank: 83
JBIO Sharpe Ratio Rank: 86
JBIO Sortino Ratio Rank: 82
JBIO Omega Ratio Rank: 79
JBIO Calmar Ratio Rank: 87
JBIO Martin Ratio Rank: 84

CRSP

CRSP Risk / Return Rank: 64
CRSP Sharpe Ratio Rank: 67
CRSP Sortino Ratio Rank: 66
CRSP Omega Ratio Rank: 62
CRSP Calmar Ratio Rank: 65
CRSP Martin Ratio Rank: 61

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JBIO vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Jade Biosciences, Inc (JBIO) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	JBIO	CRSP	Difference
Sharpe ratio: Return per unit of total volatility	1.85	0.80	+1.04
Sortino ratio: Return per unit of downside risk	2.47	1.52	+0.96
Omega ratio: Gain probability vs. loss probability	1.30	1.18	+0.12
Calmar ratio: Return relative to maximum drawdown	3.75	1.18	+2.56
Martin ratio: Return relative to average drawdown	7.99	1.99	+6.00
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

JBIO vs. CRSP - Sharpe Ratio Comparison

The current JBIO Sharpe Ratio is 1.85, which is higher than the CRSP Sharpe Ratio of 0.80. The chart below compares the historical Sharpe Ratios of JBIO and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	JBIO	CRSP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.85	0.80	+1.04
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.21	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.29	0.24	-0.53

Drawdowns

JBIO vs. CRSP - Drawdown Comparison

The maximum JBIO drawdown since its inception was -95.41%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for JBIO and CRSP.

Drawdown Indicators

	JBIO	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-95.41%	-85.11%	-10.30%
Max Drawdown (1Y) Largest decline over 1 year	-39.23%	-42.25%	+3.02%
Max Drawdown (3Y) Largest decline over 3 years	-95.41%	-64.91%	-30.50%
Max Drawdown (5Y) Largest decline over 5 years	—	-80.68%	—
Current Drawdown Current decline from peak	-84.22%	-72.89%	-11.33%
Average Drawdown Average peak-to-trough decline	-57.41%	-49.18%	-8.23%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.35%	24.97%	-6.62%

Volatility

JBIO vs. CRSP - Volatility Comparison

Jade Biosciences, Inc (JBIO) has a higher volatility of 18.82% compared to CRISPR Therapeutics AG (CRSP) at 17.25%. This indicates that JBIO's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JBIO	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.82%	17.25%	+1.57%
Volatility (6M) Calculated over the trailing 6-month period	51.60%	43.41%	+8.19%
Volatility (1Y) Calculated over the trailing 1-year period	79.60%	62.30%	+17.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	94.08%	60.58%	+33.50%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	94.08%	64.33%	+29.75%

Dividends

JBIO vs. CRSP - Dividend Comparison

Neither JBIO nor CRSP has paid dividends to shareholders.

Position	TTM	2025
CRSP CRISPR Therapeutics AG	0.00%	0.00%
JBIO Jade Biosciences, Inc	0.00%	15.55%

Financials

Frequently Asked Questions

Can I hold both JBIO and CRSP in my portfolio?

JBIO and CRSP have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, JBIO or CRSP?

JBIO has higher volatility (18.82%) compared to CRSP (17.25%). In terms of maximum drawdown, JBIO dropped -95.41% vs CRSP's -85.11%.

Which has better risk-adjusted returns?

JBIO currently has the higher Sharpe Ratio (1.85 vs 0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.